Catarina Edfjäll
Keine laufenden Positionen mehr
Vermögen: - $ am 31.03.2024
Profil
Catarina Edfjäll formerly worked at The Cancer Drug Development Forum, as Director from 2008 to 2012, International Collaboration On Rare Diseases & Orphan Drugs, as Director from 2014 to 2021, ObsEva SA, as Independent Director from 2021 to 2024, and CSL Behring AG, as Global Head-Regulatory Affairs from 2013 to 2019.
Dr. Edfjäll received her doctorate degree from the University of Basel and graduate degree from the University of Strasbourg.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
OBSEVA SA
-.--% | 24.03.2023 | 0 ( -.--% ) | - $ | 31.03.2024 |
Ehemalige bekannte Positionen von Catarina Edfjäll
| Unternehmen | Position | Ende |
|---|---|---|
| OBSEVA SA | Director/Board Member | 18.03.2024 |
| International Collaboration On Rare Diseases & Orphan Drugs | Director/Board Member | 01.01.2021 |
CSL Behring AG
 CSL Behring AG BiotechnologyHealth Technology Part of CSL Ltd., CSL Behring AG is a Swiss company that develops biological products. The private company is based in Bern, Switzerland. | General Counsel | 01.01.2019 |
| The Cancer Drug Development Forum | Director/Board Member | 01.01.2012 |
Ausbildung von Catarina Edfjäll
| University of Basel | Doctorate Degree |
| University of Strasbourg | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| OBSEVA SA | Health Technology |
| Private Unternehmen | 3 |
|---|---|
CSL Behring AG
CSL Behring AG BiotechnologyHealth Technology Part of CSL Ltd., CSL Behring AG is a Swiss company that develops biological products. The private company is based in Bern, Switzerland. | Health Technology |
| The Cancer Drug Development Forum | |
| International Collaboration On Rare Diseases & Orphan Drugs |
